A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

NCT03066778 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

453

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer (SCLC)

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Normal saline solution
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Etoposide

Sponsor

Merck Sharp & Dohme LLC